



偉俊生物科技有限公司

Wai Chun Bio-Technology Limited

*(Incorporated in the Cayman Islands with limited liability)*

(Stock code: 660)

25 August 2025

*To the Independent Shareholders*

Dear Sir or Madam,

**CONNECTED TRANSACTION:  
PROPOSED ISSUE OF NEW CONVERTIBLE BONDS  
UNDER SPECIFIC MANDATE**

We refer to the circular of the Company dated 25 August 2025 (the “Circular”), of which this letter forms part. Unless otherwise indicated, capitalised terms used herein shall have the same meanings as those defined in the Circular.

The Independent Board Committee has been formed to consider and advise you in respect of the Subscription Agreement (as amended by the Supplemental Agreements) and the transactions contemplated thereunder (including the grant of the New Convertible Bonds Specific Mandate), details of which are set out in the “Letter from the Board” contained in the Circular. INCU has been appointed as the independent financial adviser to advise the Independent Board Committee and the Independent Shareholders in this regard. The text of the letter of advice from IFA containing its recommendations and the principal factors and reasons in which INCU has taken into consideration in arriving at its recommendations is set out on pages 34 to 70 of the Circular.


Having considered the terms and conditions of the Subscription Agreement (as amended by the Supplemental Agreements) and the transactions contemplated thereunder (including the grant of the New Convertible Bonds Specific Mandate), and after taking into account the principal factors and reasons and the advice of IFA as set out in the “Letter from IFA”, contained in the Circular, we consider that the terms of the Subscription Agreement (as amended by the Supplemental Agreements) and the transactions contemplated thereunder (including the grant of the New Convertible Bonds Specific Mandate), though not in the ordinary and usual course of business of the Group, are on normal commercial terms, fair and reasonable so far as the Company and the Independent Shareholders are concerned and in the interests of the Company and the Shareholders as a whole.

Accordingly, we recommend the Independent Shareholders to vote in favour of the ordinary resolutions to be proposed at the EGM in respect of the Subscription Agreement (as amended by the Supplemental Agreements) and the transactions contemplated respectively thereunder (including the grant of the New Convertible Bonds Specific Mandate).


Yours faithfully  
For and on behalf of the  
Independent Board Committee  
Wal Chun Bio-Technology Limited



Mr. Wong Po Keung  
Independent  
non-executive Director



Mr. Wang Ziniu  
Independent  
non-executive Director



Ms. Xu Hailing  
Independent  
non-executive Director